US Stock MarketDetailed Quotes
SVRA Savara
- 3.760
- +0.110+3.01%
Close Oct 18 16:00 ET
- 3.580
- -0.180-4.79%
Post 20:01 ET
618.90MMarket Cap-8952P/E (TTM)
3.805High3.545Low1.54MVolume3.650Open3.650Pre Close5.65MTurnover1.46%Turnover RatioLossP/E (Static)164.60MShares5.70052wk High6.08P/B396.39MFloat Cap3.11552wk Low--Dividend TTM105.42MShs Float9414.996Historical High--Div YieldTTM7.12%Amplitude0.690Historical Low3.666Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Savara Stock Forum
Savara Announces Expanded Access Program (Eap) for Molgramostim Inhalation Solution (Molgramostim) for Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap)
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) has announced the Savara Early Access Program, an Expanded Access Program (EAP) for molgramostim inhalation solution to treat patients with autoimmune pulmonary alveolar proteinosis (aPAP). This program allows physicians to request molgramostim for eligible aPAP patients in select re...
Gapping up
$Boeing (BA.US)$ shares rose by 4.1% in premarket US trading on Monday after the company tentatively agreed to a 25% pay increase for its biggest union, possibly averting a damaging strike.
Crypto-related stocks such as digital coin exchange $Coinbase (COIN.US)$ and crypto miners $CleanSpark (CLSK.US)$ and $MARA Holdings (MARA.US)$ advanced prior to the opening bell, buoyed by Bitcoin's gain, which ex...
📊⚡️📊
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
Savara Inc. (Nasdaq: SVRA) presented new data from the Phase 3 IMPALA-2 trial of molgramostim for autoimmune Pulmonary Alveolar Proteinosis (aPAP)at the ERS Congress 2024. The trial met its primary endpoint, showing significant i...
1 HOUR AGO, 6:45 AM EDT
VIA BUSINESSWIRE
Mean Change From Baseline in Disease Severity Score (DSS) Showed Significant Improvement with Molgramostim Compared with Placebo at Wee...
Savara to Present New Data From Pivotal Phase 3 Impala-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the European Respiratory Society (Ers) Congress 2024 September 7th thru 11th
No comment yet